Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk Stratification of Non-Relapse Mortality After Allogeneic Hematopoietic Stem Cell Transplantation Based on Pre-Transplant Sarcopenia and HCT-CI.

Blood cell therapy·2026
Same author

Tolerance to extracellular acidic pH facilitates tumor plasticity.

Cell reports·2026
Same author

Diterpene Molecular Glue Stabilizes Protein-Protein Interactions of a Disordered Phosphoprotein that Controls Translational Repression.

JACS Au·2026
Same author

Identification of Inhibitors for eIF5A2-Dependent Translation Elongation by Monitoring the Translational Efficiency of Polyproline Motif in Mitochondrial Fission Regulator 1.

Biological & pharmaceutical bulletin·2026
Same author

Polyamines stimulate the protein synthesis of the translation initiation factor eIF5A2, participating in mRNA decoding, distinct from eIF5A1.

The Journal of biological chemistry·2025
Same author

Harnessing Microalgae as Sustainable Cell Factories for Polyamine-Based Nanosilica for Biomedical Applications.

Molecules (Basel, Switzerland)·2025

Related Experiment Video

Updated: May 25, 2026

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

PRAS40 is a functionally critical target for EWS repression in Ewing sarcoma.

Lin Huang1, Yuji Nakai, Iku Kuwahara

  • 1Molecular Entomology Laboratory, RIKEN, 2-1 Hirosawa, Wako, Saitama, Japan.

Cancer Research
|January 14, 2012
PubMed
Summary

Ewing sarcoma family tumors (ESFT) require additional events beyond EWS/FLI-1. Researchers found PRAS40 is an EWS target gene promoting ESFT development and metastasis, suggesting it as a new therapeutic target.

More Related Videos

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

Related Experiment Videos

Last Updated: May 25, 2026

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Ewing sarcoma family tumors (ESFT) are aggressive, metastatic cancers driven by the EWS/FLI-1 fusion gene.
  • Carcinogenesis in ESFT requires additional genetic events beyond EWS/FLI-1 expression.

Purpose of the Study:

  • To identify novel EWS target genes involved in ESFT development.
  • To investigate the role of Akt substrate PRAS40 in ESFT pathogenesis.

Main Methods:

  • Identified PRAS40 as an EWS target gene.
  • Investigated EWS regulation of PRAS40 mRNA.
  • Utilized Akt inhibitors and siRNA-mediated PRAS40 knockdown in ESFT cell lines.
  • Analyzed protein levels of EWS and PRAS40 in ESFT cells.

Main Results:

  • EWS negatively regulates PRAS40 expression by binding its 3' untranslated region.
  • Akt inhibition and PRAS40 knockdown suppressed ESFT cell proliferation and metastasis.
  • PRAS40 knockdown reversed increased proliferation caused by EWS knockdown.
  • Inverse protein levels of EWS and PRAS40 were observed in ESFT cells.

Conclusions:

  • PRAS40 promotes ESFT development and progression.
  • PRAS40 represents a potential novel therapeutic target for ESFT.
  • Understanding EWS-PRAS40 interactions is crucial for ESFT treatment strategies.